

Special Issue

Epidemiology, Vaccinology and Surveillance of COVID-19

Message from the Guest Editors

At present, COVID-19 is still a global pandemic, and SARS-CoV-2 is constantly evolving and mutating, producing variants with different transmissibility and virulence. The rapid spread of COVID-19 causes enormous impacts on social, economic, and healthcare systems in the world. Effective treatments to block the spread of COVID-19 have not been developed yet, so countries implement a series of nontreatment interventions, such as social distancing, isolation, face masks, and quarantine, to reduce its rapid transmission. Therefore, we would like to encourage the presentation to this Special Issue of the molecular characterization of different SARS-CoV-2 variants and the epidemiological characterization of the COVID-19 caused by them. Given that the COVID-19 vaccine can effectively reduce the infection rate and severity rate of COVID-19, topics concerning vaccine effectiveness, safety, willingness to vaccinate, and hesitancy of vaccinating against COVID-19 will also be welcome. Adding new information on these topics could provide a better understanding of the pathogenesis of COVID-19 and help design new surveillance and prevention strategies.

Guest Editors

Prof. Dr. Min Liu

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, No. 38, Xueyuan Road, Haidian District, Beijing 100191, China

Dr. Jue Liu

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China

Deadline for manuscript submissions

closed (30 June 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/129769

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).